New York, USA — October 2, 2025 — Leads & Copy — CRISPR therapies are showing significant potential in clinical trials, offering precise gene-editing solutions for treating genetic disorders and other complex diseases, according to DelveInsight. The rising prevalence of genetic conditions is driving adoption, and emerging CRISPR-based therapies are expected to further expand market opportunities.
DelveInsight’s ‘CRISPR Therapies Pipeline Insight 2025’ report provides comprehensive global coverage of pipeline CRISPR therapies in various stages of clinical development. Major pharmaceutical companies are actively working to advance the pipeline space and future growth potential of the CRISPR therapies pipeline domain, the report finds.
Key findings from the report include a robust space with 25+ active players working to develop 30+ pipeline CRISPR therapies. Key companies such as Locus Biosciences, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Tango Therapeutics, KSQ Therapeutics, Emendo Biotherapeutics, Beam Therapeutics, Excision BioTherapeutics, Eli Lilly and Company, Epicrispr Biotechnologies, Inc., and Scribe Therapeutics, are evaluating new CRISPR therapies to improve the treatment landscape.
Promising pipeline CRISPR therapies such as LBP-EC01, NTLA-2002, CB-010, TNG260, KSQ-4279, EMD-101, BEAM-301, EBT-101, VERVE-201, EPI 331, and STX-1150 are under different phases of clinical trials.
Recent activities include:
- In September 2025, Intellia Therapeutics, Inc. announced it had completed enrollment in the global Phase III HAELO study of lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE).
- In July 2025, Eli Lilly and Company announced the successful completion of its acquisition of Verve Therapeutics, Inc. and its in vivo gene editors for up to USD 1.3 billion.
- In June 2025, Intellia Therapeutics, Inc. announced three-year follow-up data from the Phase I portion of the ongoing Phase I/II study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002).
- In January 2025, Caribou Biosciences, Inc. announced initiation of the GALLOP Phase I clinical trial evaluating CB-010 in patients with lupus nephritis (LN) and extrarenal lupus (ERL).
- In January 2025, Intellia Therapeutics, Inc. announced that the first patient had been dosed in the global Phase III study of NTLA-2002 for the treatment of hereditary angioedema (HAE).
- In September 2024, Caribou Biosciences, Inc. announced that the US Food and Drug Administration (FDA) granted Fast Track designation to CB-010 for refractory systemic lupus erythematosus (SLE).
- In August 2024, Locus Biosciences, Inc. announced positive results from Part 1 of its two-part Phase II ELIMINATE trial evaluating LBP-EC01, a CRISPR-Cas3 genetically engineered bacteriophage therapy designed to treat patients with uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli).
The report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the clinical trial landscape.
Contact:
Shruti Thakur
info@delveinsight.com
+14699457679
Source: DelveInsight
